Search

Streptococcus pneumoniae type 6b capsular polysaccharide antigen

Streptococcus pneumoniae type 6b capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 6b of *Streptococcus pneumoniae*

Streptococcus pneumoniae type 7f capsular polysaccharide antigen

Streptococcus pneumoniae type 7f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 7f of *Streptococcus pneumoniae*

Streptococcus pneumoniae type 9v capsular polysaccharide antigen

Streptococcus pneumoniae type 9v capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 9v of *Streptococcus pneumoniae*

Streptococcus pneumoniae type 19f capsular polysaccharide antigen

Streptococcus pneumoniae type 19f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 19f of *Streptococcus pneumoniae

Repinotan

Repinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.

CX-2009

CX-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors).

R-30490

R-30490 was found to be the most selective agonist for the mu opioid receptor out of all the fentanyl analogues tested, but it has never been introduced for medical use in humans, although the closely … It was first synthesized by Janssen Pharmaceutica as part of a structure-activity relationship study of fentanly and its derivatives.

ANZ-100

Nirmatrelvir

[L39544] It was fully approved by the FDA on May 25, 2023. … [L33354] 3CL^PRO is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2.

Brilliant blue G

Brilliant blue G, like its name, imparts a vibrant blue color, facilitating identification of the ILM. It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830] … Brilliant Blue G is used in an ophthalmic solution for staining the internal limiting membrane (ILM) of the eye during ophthalmic procedures.